Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Avenue
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
17
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 4.30 | -0.05% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,095.70 | 26.04 | 0.20% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,728.80 | 1.50 | -0.02% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |